{"title":"1990-2021年全球、地区和国家抑郁症负担:预测到2040年的分解和年龄期队列分析","authors":"Qianshu Xu, Zhengxue Qiao, Yuecui Kan, Bowen Wan, Xiaohui Qiu, Yanjie Yang","doi":"10.1016/j.jad.2025.120018","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Depression stands as one of the leading causes of disability worldwide. This study conducts a comprehensive analysis of the global burden of depression.</p><p><strong>Methods: </strong>Based on the Global Burden of Disease (GBD), we employed Joinpoint regression to analyze trends disease burden of depression globally from 1990 to 2021. The age-period-cohort (APC) model was employed to decompose the effects of age, period, and cohort, while the Das Gupta method quantified the contributions of aging, population growth, and epidemiological changes. A Bayesian age-period-cohort (BAPC) model was further utilized to project disease burden through 2040.</p><p><strong>Results: </strong>In 2021, the global age-standardized incidence, prevalence, and DALY rates of depression increased by 15.6 %, 11.3 %, and 13.4 %, compared to 1990, with average annual percentage changes (AAPCs) of 0.5 %, 0.4 %, and 0.4 %. APC analysis identified a peak age effect at 60-64 years, the highest period risk during 2017-2021, and a continuous rise in cohort risk after 1987. Cross-national inequality analysis revealed a higher burden in low-SDI countries (SII = -1981.7 per 100,000 in 2021), alongside widening health disparities among females. Decomposition analysis indicated that population growth accounted for 43.5 %-54.2 % of the global burden increase. BAPC projections estimated that by 2040, global age-standardized incidence, prevalence, and DALY rates would rise to 8478.2, 6927.8, and 1248.1 per 100,000.</p><p><strong>Conclusions: </strong>The global burden of depression continues to rise with significant inequalities. Prioritizing women, high-growth regions, and low-SDI countries is essential to address the escalating burden. This study provides critical evidence for optimizing resource allocation and developing interdisciplinary intervention plans.</p>","PeriodicalId":14963,"journal":{"name":"Journal of affective disorders","volume":" ","pages":"120018"},"PeriodicalIF":4.9000,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Global, regional, and national burden of depression, 1990-2021: a decomposition and age-period-cohort analysis with projection to 2040.\",\"authors\":\"Qianshu Xu, Zhengxue Qiao, Yuecui Kan, Bowen Wan, Xiaohui Qiu, Yanjie Yang\",\"doi\":\"10.1016/j.jad.2025.120018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Depression stands as one of the leading causes of disability worldwide. This study conducts a comprehensive analysis of the global burden of depression.</p><p><strong>Methods: </strong>Based on the Global Burden of Disease (GBD), we employed Joinpoint regression to analyze trends disease burden of depression globally from 1990 to 2021. The age-period-cohort (APC) model was employed to decompose the effects of age, period, and cohort, while the Das Gupta method quantified the contributions of aging, population growth, and epidemiological changes. A Bayesian age-period-cohort (BAPC) model was further utilized to project disease burden through 2040.</p><p><strong>Results: </strong>In 2021, the global age-standardized incidence, prevalence, and DALY rates of depression increased by 15.6 %, 11.3 %, and 13.4 %, compared to 1990, with average annual percentage changes (AAPCs) of 0.5 %, 0.4 %, and 0.4 %. APC analysis identified a peak age effect at 60-64 years, the highest period risk during 2017-2021, and a continuous rise in cohort risk after 1987. Cross-national inequality analysis revealed a higher burden in low-SDI countries (SII = -1981.7 per 100,000 in 2021), alongside widening health disparities among females. Decomposition analysis indicated that population growth accounted for 43.5 %-54.2 % of the global burden increase. BAPC projections estimated that by 2040, global age-standardized incidence, prevalence, and DALY rates would rise to 8478.2, 6927.8, and 1248.1 per 100,000.</p><p><strong>Conclusions: </strong>The global burden of depression continues to rise with significant inequalities. Prioritizing women, high-growth regions, and low-SDI countries is essential to address the escalating burden. This study provides critical evidence for optimizing resource allocation and developing interdisciplinary intervention plans.</p>\",\"PeriodicalId\":14963,\"journal\":{\"name\":\"Journal of affective disorders\",\"volume\":\" \",\"pages\":\"120018\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of affective disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jad.2025.120018\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of affective disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jad.2025.120018","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Global, regional, and national burden of depression, 1990-2021: a decomposition and age-period-cohort analysis with projection to 2040.
Background: Depression stands as one of the leading causes of disability worldwide. This study conducts a comprehensive analysis of the global burden of depression.
Methods: Based on the Global Burden of Disease (GBD), we employed Joinpoint regression to analyze trends disease burden of depression globally from 1990 to 2021. The age-period-cohort (APC) model was employed to decompose the effects of age, period, and cohort, while the Das Gupta method quantified the contributions of aging, population growth, and epidemiological changes. A Bayesian age-period-cohort (BAPC) model was further utilized to project disease burden through 2040.
Results: In 2021, the global age-standardized incidence, prevalence, and DALY rates of depression increased by 15.6 %, 11.3 %, and 13.4 %, compared to 1990, with average annual percentage changes (AAPCs) of 0.5 %, 0.4 %, and 0.4 %. APC analysis identified a peak age effect at 60-64 years, the highest period risk during 2017-2021, and a continuous rise in cohort risk after 1987. Cross-national inequality analysis revealed a higher burden in low-SDI countries (SII = -1981.7 per 100,000 in 2021), alongside widening health disparities among females. Decomposition analysis indicated that population growth accounted for 43.5 %-54.2 % of the global burden increase. BAPC projections estimated that by 2040, global age-standardized incidence, prevalence, and DALY rates would rise to 8478.2, 6927.8, and 1248.1 per 100,000.
Conclusions: The global burden of depression continues to rise with significant inequalities. Prioritizing women, high-growth regions, and low-SDI countries is essential to address the escalating burden. This study provides critical evidence for optimizing resource allocation and developing interdisciplinary intervention plans.
期刊介绍:
The Journal of Affective Disorders publishes papers concerned with affective disorders in the widest sense: depression, mania, mood spectrum, emotions and personality, anxiety and stress. It is interdisciplinary and aims to bring together different approaches for a diverse readership. Top quality papers will be accepted dealing with any aspect of affective disorders, including neuroimaging, cognitive neurosciences, genetics, molecular biology, experimental and clinical neurosciences, pharmacology, neuroimmunoendocrinology, intervention and treatment trials.